Advertisement
Advertisement

KPTI

KPTI logo

Karyopharm Therapeutics Inc.

8.69
USD
Sponsored
+0.52
+6.39%
Jan 09, 15:59 UTC -5
Closed
exchange

After-Market

8.68

-0.01
-0.14%

KPTI Earnings Reports

Positive Surprise Ratio

KPTI beat 24 of 40 last estimates.

60%

Next Report

Date of Next Report
Feb 17, 2026
Estimate for Q4 25 (Revenue/ EPS)
$36.56M
/
-$2.11
Implied change from Q3 25 (Revenue/ EPS)
-16.99%
/
-44.76%
Implied change from Q4 24 (Revenue/ EPS)
+19.71%
/
-41.39%

Karyopharm Therapeutics Inc. earnings per share and revenue

On Nov 03, 2025, KPTI reported earnings of -3.82 USD per share (EPS) for Q3 25, missing the estimate of -3.19 USD, resulting in a -19.63% surprise. Revenue reached 44.04 million, compared to an expected 42.04 million, with a 4.78% difference. The market reacted with a +4.66% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -2.11 USD, with revenue projected to reach 36.56 million USD, implying an decrease of -44.76% EPS, and decrease of -16.99% in Revenue from the last quarter.
FAQ
For Q3 2025, Karyopharm Therapeutics Inc. reported EPS of -$3.82, missing estimates by -19.63%, and revenue of $44.04M, 4.78% above expectations.
The stock price moved up 4.66%, changed from $5.80 before the earnings release to $6.07 the day after.
The next earning report is scheduled for Feb 17, 2026.
Based on 8 analysts, Karyopharm Therapeutics Inc. is expected to report EPS of -$2.11 and revenue of $36.56M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement